General Information of Drug Combination (ID: DCZL2D8)

Drug Combination Name
Imipenem Idarubicin
Indication
Disease Entry Status REF
Glioblastoma? Investigative [1]
Component Drugs Imipenem   DMI9FBP Idarubicin   DMM0XGL
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: T98G
Zero Interaction Potency (ZIP) Score: 3.74
Bliss Independence Score: 3.74
Loewe Additivity Score: 0.98
LHighest Single Agent (HSA) Score: 0.98

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Imipenem
Disease Entry ICD 11 Status REF
Bacteremia 1A73 Approved [2]
Bacterial infection 1A00-1C4Z Approved [3]
Endometritis N.A. Approved [2]
Peritonitis N.A. Approved [2]
Pelvic inflammatory disease GA05 Investigative [2]
Imipenem Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Penicillin binding protein 2 (Bact mrdA) TTHWB7G MRDA_ECOLI Binder [6]
------------------------------------------------------------------------------------
Imipenem Interacts with 17 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Beta-lactamase (blaB) DEC3G7M A0A1S7IV31_ENTAS Metabolism [7]
Beta-lactamase (blaB) DE7IH52 AMPC_CITFR Metabolism [8]
AmpC beta-lactamase (ampC) DERI7LO A0A0H3KQ39_BURM1 Metabolism [9]
Beta-lactamase (blaB) DEYIEO5 AMPC_SERMA Metabolism [8]
Beta-lactamase (blaB) DEBKS91 A0A1B1FBM9_ACIBA Metabolism [10]
Beta-lactamase (blaB) DEUHIQS A0A1S7IV31_ENTAS Metabolism [11]
Beta-lactamase (blaB) DECWSA9 AMPC_MORMO Metabolism [12]
Carbapenemase (cphA) DEB90AL BLAB_AERHY Metabolism [13]
Carbapenemase (cphA) DETRKSD A0A3G1JAD7_ALCXX Metabolism [14]
Beta-lactamase (blaB) DECB2MX A0A1M5PLB6_9FLAO Metabolism [15]
Beta-lactamase (blaB) DEEQ3RW K0GG60_CITBR Metabolism [16]
Carbapenemase (cphA) DEQ4LIN Q8L1M8_9ENTR Metabolism [17]
Beta-lactamase (blaB) DEQ0K5J A0A223JZR3_9ENTR Metabolism [16]
Beta-lactamase (blaB) DE7MYGB A0A291NY45_PROSP Metabolism [8]
Carbapenemase (cphA) DE9QNXV A0A366EJX1_9ENTR Metabolism [18]
Beta-lactamase (blaB) DEL6894 A0A2S8DM15_SHIBO Metabolism [16]
Beta-lactamase (blaB) DE8KH4C A0A3B7D7C4_9VIBR Metabolism [19]
------------------------------------------------------------------------------------
⏷ Show the Full List of 17 DME(s)
Imipenem Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [20]
------------------------------------------------------------------------------------
Indication(s) of Idarubicin
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [4]
Acute myeloid leukaemia 2A60 Approved [5]
Adult acute monocytic leukemia N.A. Approved [4]
Childhood acute megakaryoblastic leukemia N.A. Approved [4]
Leukemia N.A. Approved [4]
Idarubicin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Modulator [22]
------------------------------------------------------------------------------------
Idarubicin Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [23]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [24]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [24]
------------------------------------------------------------------------------------
Idarubicin Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [25]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [25]
------------------------------------------------------------------------------------
Idarubicin Interacts with 9 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Decreases Activity [21]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [26]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Increases Activity [21]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Increases Expression [27]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Decreases Activity [21]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [28]
Peroxisome proliferator-activated receptor delta (PPARD) OTI4WTOP PPARD_HUMAN Decreases Activity [21]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [29]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Decreases Activity [21]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DOT(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Cilastatin FDA Label
3 How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
4 Idarubicin FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7083).
6 A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with gram-negative urosepsis. Urosepsis Study Group. J Endotoxin Res. 2000;6(1):25-31.
7 FRI-4 carbapenemase-producing Enterobacter cloacae complex isolated in Tokyo, Japan. J Antimicrob Chemother. 2018 Nov 1;73(11):2969-2972.
8 Antibiotic therapy for inducible AmpC beta-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents. 2012 Oct;40(4):297-305.
9 Characterization of the AmpC beta-Lactamase from Burkholderia multivorans. Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01140-18.
10 A high mortality rate associated with multidrug-resistant Acinetobacter baumannii ST79 and ST25 carrying OXA-23 in a Brazilian intensive care unit. PLoS One. 2018 Dec 28;13(12):e0209367.
11 AmpC beta-lactamase-producing Enterobacterales: what a clinician should know. Infection. 2019 Jun;47(3):363-375.
12 Molecular investigation of extended-spectrum beta-lactamase genes and potential drug resistance in clinical isolates of Morganella morganii. Ann Saudi Med. 2016 May-Jun;36(3):223-8.
13 A carbapenem-resistant clinical isolate of Aeromonas hydrophila in Japan harbouring an acquired gene encoding GES-24 beta-lactamase. J Med Microbiol. 2018 Nov;67(11):1535-1537.
14 Proteomic identification of Axc, a novel beta-lactamase with carbapenemase activity in a meropenem-resistant clinical isolate of Achromobacter xylosoxidans. Sci Rep. 2018 May 25;8(1):8181.
15 Whole-genome sequence of Chryseobacterium oranimense, a colistin-resistant bacterium isolated from a cystic fibrosis patient in France. Antimicrob Agents Chemother. 2015 Mar;59(3):1696-706.
16 Hospital sewage water: a reservoir for variants of New Delhi metallo-beta-lactamase (NDM)- and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. Int J Antimicrob Agents. 2018 Jan;51(1):82-88.
17 Occurrence of a new metallo-beta-lactamase IMP-4 carried on a conjugative plasmid in Citrobacter youngae from the People's Republic of China. FEMS Microbiol Lett. 2001 Jan 1;194(1):53-7.
18 Pseudocitrobacter gen. nov., a novel genus of the Enterobacteriaceae with two new species Pseudocitrobacter faecalis sp. nov., and Pseudocitrobacter anthropi sp. nov, isolated from fecal samples from hospitalized patients in Pakistan. Syst Appl Microbiol. 2014 Feb;37(1):17-22.
19 Carbapenemase VCC-1-producing Vibrio cholerae in coastal waters of Germany. Emerg Infect Dis. 2017 Oct;23(10):1735-1737.
20 Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
21 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
22 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
23 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
24 Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
25 In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
26 A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. J Am Soc Nephrol. 2016 Apr;27(4):1015-28. doi: 10.1681/ASN.2015010060. Epub 2015 Aug 10.
27 The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma. 2005;52(5):430-4.
28 The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts. Cell Mol Biol Lett. 2008;13(2):182-94. doi: 10.2478/s11658-007-0045-7. Epub 2008 Apr 10.
29 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.